129 related articles for article (PubMed ID: 29120811)
21. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence.
Lee YJ; Youn IK; Kim SH; Kang BJ; Park WC; Lee A
Magn Reson Imaging; 2020 Feb; 66():36-41. PubMed ID: 31785544
[TBL] [Abstract][Full Text] [Related]
23. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
24. Imaging of triple-negative breast cancer.
Dogan BE; Turnbull LW
Ann Oncol; 2012 Aug; 23 Suppl 6():vi23-9. PubMed ID: 23012298
[TBL] [Abstract][Full Text] [Related]
25. Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype.
Schmitz AM; Loo CE; Wesseling J; Pijnappel RM; Gilhuijs KG
Breast Cancer Res Treat; 2014 Dec; 148(3):541-51. PubMed ID: 25376743
[TBL] [Abstract][Full Text] [Related]
26. Age-related frequency of triple negative breast cancer in women.
Sajid MT; Ahmed M; Azhar M; Mustafa QU; Shukr I; Ahmed M; Kamal Z
J Coll Physicians Surg Pak; 2014 Jun; 24(6):400-3. PubMed ID: 24953912
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer in very young women (<30 years): Correlation of imaging features with clinicopathological features and immunohistochemical subtypes.
An YY; Kim SH; Kang BJ; Park CS; Jung NY; Kim JY
Eur J Radiol; 2015 Oct; 84(10):1894-902. PubMed ID: 26198117
[TBL] [Abstract][Full Text] [Related]
28. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
[TBL] [Abstract][Full Text] [Related]
29. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
30. The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors.
Choi WJ; Cha JH; Kim HH; Shin HJ; Chae EY
Clin Breast Cancer; 2016 Dec; 16(6):e145-e152. PubMed ID: 27566960
[TBL] [Abstract][Full Text] [Related]
31. Sonographic features of triple-negative and non-triple-negative breast cancer.
Wojcinski S; Soliman AA; Schmidt J; Makowski L; Degenhardt F; Hillemanns P
J Ultrasound Med; 2012 Oct; 31(10):1531-41. PubMed ID: 23011616
[TBL] [Abstract][Full Text] [Related]
32. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
36. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
37. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
38. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
Yu J; Gao F; Klimberg VS; Margenthaler JA
Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
[TBL] [Abstract][Full Text] [Related]
39. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
Zhang P; Xu BH; Ma F; Li Q
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]